Cefazolin non-inferior to penicillins for methicillin-susceptible Staphylococcus aureus bacteremia

1. In this international randomized controlled trial of adults with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, cefazolin was noninferior to antistaphylococcal penicillins for 90-day mortality. 2. Cefazolin was also associated with fewer adverse events, particularly lower rates of acute kidney injury and treatment discontinuation due to toxicity. Evidence Rating Level: 1…